about
Effect of substance P on rat gastrointestinal transitAirway nitric oxide diffusion in asthma: Role in pulmonary function and bronchial responsivenessExhaled nitric oxide measurements in childhood asthma: techniques and interpretation.Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years.Exhaled nitric oxide in asthma: from bench to bedside.The relationship of induced-sputum inflammatory cells to BAL and biopsy.Transforming growth factor-beta2 induces bronchial epithelial mucin expression in asthma.Preface to outcome measures in allergic rhinitis.Objective monitoring of nasal airway inflammation in rhinitis.ATS workshop proceedings: exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate.Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.Exhaled nitric oxide in pulmonary diseases: a comprehensive review.Alpha-1-antitrypsin inhibits nitric oxide production.Exhaled breath condensate: methodological recommendations and unresolved questions.Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma.Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients.Nitric oxide and protein nitration in the cystic fibrosis airway.Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma.Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.Safety and application of induced sputum analysis in childhood asthma.Increased TGF-beta2 in severe asthma with eosinophilia.A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model.Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.Asthma control in pediatric patients treated with once-daily or twice-daily nebulized budesonide inhalation suspension (Pulmicort Respules).Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma.Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma.Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma.Monitoring nitric oxide: here to stay for bench and bedside.Wildfire smoke and respiratory symptoms in patients with chronic obstructive pulmonary disease.Winter air pollution and disease parameters in advanced chronic obstructive pulmonary disease panels residing in Denver, Colorado.The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma.NO pathway in CF and non-CF children.Single-breath exhaled nitric oxide in preschool children facilitated by a servo-controlled device maintaining constant flow.A significant proportion of exhaled nitric oxide arises in large airways in normal subjects.Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury.Exhaled nitric oxide as a diagnostic tool.Assessment of exhaled nitric oxide kinetics in healthy infants.Exhaled nitric oxide concentrations: online versus offline values in healthy children.Pathophysiology of nocturnal asthma.Ensuring quality in pharmaceutical studies.
P50
Q28338587-FD31229B-25E9-4D9C-B8C9-7A98A3069230Q28376746-F528A418-12DC-4897-B876-92CBC7EBFE87Q33738565-D7033897-C02D-4EB8-A671-2A9D1954A28DQ34424366-7207643E-F139-4580-B7AD-214ACF74C2A6Q35067537-2AE82F64-5117-47C6-82CD-661BF5E26A7BQ35082427-C20E0E2D-65DC-461A-AD0A-CFA35441E0E9Q35103250-ECC60053-EBD1-428F-A186-CB3C0354E36FQ36061495-4AA60624-7B6D-496C-82A9-14A8E52FA2B1Q36061505-1A108EDB-33AE-4039-A427-14F915834825Q36432168-EBA1A80A-2D60-4654-BD1C-59064446DBD1Q36632054-5BB353A7-8406-4765-9B85-BE23702BBD77Q37786111-0C88009A-BF84-4686-AC5D-3B4E43CA06ABQ39279412-01338075-4712-4652-9F64-08F8DB56A01EQ40392502-0558067A-EE54-4E6D-B181-983051B670F1Q42971404-2ADB40FF-F942-4C3F-A270-83F33ECCDF55Q43604746-DA19E260-B37A-4DF8-8D2E-823AF7CDFBF1Q44137986-1ADABF74-61A6-4F1C-8969-10D5A8A69A1CQ44447258-2AD67F4C-EDA8-4B39-808E-02D350E52CA9Q44827172-2A99FD13-9FE7-4B6B-80B6-11B69E8C33D5Q45051022-418E0994-9ACA-46A1-BB37-9AE482950CC2Q45215090-431AE027-6D9D-4BAD-979A-E002AC042C04Q45994046-2368A2D4-80DE-4DBD-A863-9CB1D1ABFD32Q46281641-7CFF8701-1C4D-4584-B882-9894A59AC8F3Q46556350-25D0BF46-46F1-4B78-A8FB-C926F46FF845Q46609914-5502324E-E30E-4FED-98F6-2AF84667FB4AQ46913738-85549AA0-303C-4614-9C1D-5D835C304375Q47678362-CC16AAB0-BF7A-44CF-9FD9-803B48C80521Q47787879-0C907B38-1569-4070-B191-A95DD80A1226Q47852676-B4D5B8B6-8494-44F7-B3B0-81D47F5B6B0AQ47852717-008E2381-A9BE-4290-9689-7B4ADA7E2F4FQ47897674-A6CE76BD-A193-4E37-83FF-F62ECE54FB5AQ47948993-D1525DFA-9A86-405E-9330-51ED6B3CAFEEQ47988369-D8631DF9-AF4A-4CEF-B9E6-1E23F5E8622FQ51497246-F489CB0C-DB7D-4873-B5D6-A11FBA42D613Q51503226-20AA9AD2-1526-432B-85C2-A1BF0D73B1E4Q51685946-72613F3D-B54F-486E-B6FA-D3CF5E767680Q51688279-356303B8-4CBC-455A-89C1-E6B7D5474A14Q51722416-78A3644B-0CAF-4162-8B19-78047D7990A0Q52181349-26736477-04DB-484A-A6E3-3172695A1EB3Q52955853-48B3FE3F-F555-4A8D-94EA-60E79C93B2D2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philip Silkoff
@ast
Philip Silkoff
@en
Philip Silkoff
@es
Philip Silkoff
@nl
Philip Silkoff
@sl
type
label
Philip Silkoff
@ast
Philip Silkoff
@en
Philip Silkoff
@es
Philip Silkoff
@nl
Philip Silkoff
@sl
prefLabel
Philip Silkoff
@ast
Philip Silkoff
@en
Philip Silkoff
@es
Philip Silkoff
@nl
Philip Silkoff
@sl
P1053
S-9037-2016
P106
P21
P31
P3829
P496
0000-0001-6018-5199